FY2025 EPS Estimates for Globus Medical Raised by Analyst

Globus Medical, Inc. (NYSE:GMED) – Analysts at Zacks Research upped their FY2025 earnings per share estimates for Globus Medical in a report released on Friday, October 24th. Zacks Research analyst Team now anticipates that the medical device company will post earnings of $3.21 per share for the year, up from their prior estimate of $3.20. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s FY2026 earnings at $3.64 EPS, Q1 2027 earnings at $0.89 EPS and Q3 2027 earnings at $1.12 EPS.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, August 7th. The medical device company reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.76 by $0.10. Globus Medical had a return on equity of 10.65% and a net margin of 13.58%.The company had revenue of $745.34 million for the quarter, compared to the consensus estimate of $738.91 million. During the same quarter in the previous year, the business earned $0.75 earnings per share. The company’s revenue for the quarter was up 18.4% on a year-over-year basis.

A number of other equities research analysts also recently commented on the company. Royal Bank Of Canada set a $88.00 target price on Globus Medical in a research report on Friday, October 10th. Wall Street Zen downgraded Globus Medical from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Weiss Ratings restated a “hold (c)” rating on shares of Globus Medical in a research report on Wednesday, October 8th. Canaccord Genuity Group reduced their target price on Globus Medical from $97.00 to $90.00 and set a “buy” rating on the stock in a research report on Tuesday, July 22nd. Finally, Wells Fargo & Company reduced their target price on Globus Medical from $76.00 to $66.00 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Eight analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Globus Medical presently has a consensus rating of “Moderate Buy” and an average price target of $87.27.

Globus Medical Stock Up 1.8%

NYSE:GMED opened at $63.41 on Monday. Globus Medical has a 52 week low of $51.79 and a 52 week high of $94.93. The company has a market capitalization of $8.56 billion, a P/E ratio of 24.39, a P/E/G ratio of 1.71 and a beta of 1.12. The stock’s fifty day moving average is $59.36 and its two-hundred day moving average is $60.40.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its stake in Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in Globus Medical during the 2nd quarter worth approximately $28,000. First Horizon Corp acquired a new stake in Globus Medical during the 3rd quarter worth approximately $31,000. Larson Financial Group LLC lifted its position in Globus Medical by 1,007.7% during the 1st quarter. Larson Financial Group LLC now owns 432 shares of the medical device company’s stock worth $32,000 after acquiring an additional 393 shares during the period. Finally, CENTRAL TRUST Co acquired a new stake in Globus Medical during the 2nd quarter worth approximately $39,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Insiders Place Their Bets

In other Globus Medical news, Director Ann D. Rhoads sold 10,000 shares of the company’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $58.46, for a total transaction of $584,600.00. Following the sale, the director owned 25,384 shares in the company, valued at $1,483,948.64. This represents a 28.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 18.51% of the stock is currently owned by company insiders.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.